Perioperative Hemostasis Management in Liver Transplantation
NCT ID: NCT06257407
Last Updated: 2024-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1200 participants
OBSERVATIONAL
2024-10-17
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The need for transfusions has largely decreased over the last 20 years, and currently around 20-25% of patients are transfused (transfusion of at least 1 blood product during LT). However, massive transfusion is necessary in 10% of LT. The European Society of Anaesthesiology (ESA) has issued recommendations on the management of severe bleeding during surgery. However, these recommendations are not specific to LT. Moreover, transfusion strategies vary widely from one center to another. The implementation of protocols within teams dedicated to LT has led to a reduction in bleeding and transfusion, with or without the use of viscoelastic testing.
Intraoperative bleeding and transfusion requirements, as well as postoperative thromboembolic complications, remain difficult to predict. Predictive models of bleeding risk have been developed, but they are based solely on preoperative characteristics and do not take into account the course and various phases of the operation. In addition, new methods such as Bayesian inference or machine learning have been developed, and seem capable of providing different information from that obtained by conventional models.
The overall aim of this prospective multicenter observational study is to investigate the risk factors for bleeding and thrombosis in per- and post-operative LT using different predictive methods, and to describe the management of bleeding and post-operative anticoagulation in metropolitan France.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.
NCT02352181
Fibrinogen and Intraoperative Bleeding in Liver Transplant
NCT04925843
Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy
NCT00657384
Point-of-care Management of Coagulopathy in Lung Transplantation
NCT03598907
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
NCT04265157
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults Patients with Liver transplant
No intervention during this observational study. Patient who meet the inclusion criteria will be included
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Liver transplant patient
Exclusion Criteria
* Protected populations: under guardianship or curatorship
* Patients not affiliated to a social security scheme
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoire français de Fractionnement et de Biotechnologies
INDUSTRY
Société Française d'Anesthésie et de Réanimation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
WEISS, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Beaujon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chru Minjoz
Besançon, , France
CHU Estaing
Clermont, , France
Hôpital Beaujon
Clichy, , France
CHU Grenoble Alpes
Grenoble, , France
CHU Claude Huriez
Lille, , France
Hôpital de la Croix-Rousse
Lyon, , France
CHU La Timone
Marseille, , France
Hôpital St Eloi
Montpellier, , France
Hôpital De L'Archet 2
Nice, , France
CHU Pitié-Salpêtrière
Paris, , France
CHU Haut Levêque
Pessac, , France
CHU Pontchaillou
Rennes, , France
CHU Hautepierre
Strasbourg, , France
CHU Toulouse Rangueil
Toulouse, , France
CHU Tours
Tours, , France
Hôpital Paul Brousse
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cyrielle DESPRES, MD
Role: primary
Renaud GUERIN, MD
Role: primary
Pauline DEVAUCHELLE, MD
Role: primary
Alexandre GODON, MD
Role: primary
Anne BIGNON, MD
Role: primary
Pierre JACQUENOD Pierre, MD
Role: primary
Benedicte GRIGORESCO, MD
Role: primary
Clément MONET, MD
Role: primary
Romain ROZIER Romain, MD
Role: primary
Antoine MONSEL, MD
Role: primary
Elsa DELOGE, MD
Role: primary
Axelle MAURICE, MD
Role: primary
Paul BRUNET, MD
Role: primary
Vincent ETIENNE, MD
Role: primary
Isaure BRETEAU, MD
Role: primary
Stephanie ROULLET, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEMOTRANSPLANT / 2022-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.